Furthermore, we examined the expression of an α-SMA-a marker of hepatic fibrosis by western blot; the data showed that the level of α-SMA was both significantly ameliorated in CCl4 mice treated with rAAV8-anti-miR-497, and Smad7 downstream p-Smad2/3 protein was also considerably decreased compared with rAAV8 anti-SCR (Fig. 5d, α-SMA: control vs. anti-SCR: F(3, 12) = 9.910, P = 0.002; anti-SCR vs. anti-miR-497: F(3, 12) = 9.910, P = 0.027; p-Smad2/3: control vs. anti-SCR: F(3, 12) = 9.910, P = 0.002; anti-SCR vs. anti-miR-497: F(3, 12) = 9.910, P = 0.004). Here, SMAD7 is linked to Hepatic fibrosis.